AURINIA PHARMACEUTICALS INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 4.91 USD | +0.82% |
|
-1.60% | -45.38% |
| Mar. 20 | ILJIN SNT Delivers a Letter to Aurinia Pharmaceuticals | CI |
| Mar. 07 | Aurinia Pharmaceuticals Insider Sold Shares Worth $711,094, According to a Recent SEC Filing | MT |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 2,210 | 1,750 | 2,966 | 613.9 | 1,291 | 710.1 | - | - |
| Enterprise Value (EV) 1 | 1,904 | 1,352 | 2,499 | 224.5 | 940.5 | 366 | 319.6 | 710.1 |
| P/E ratio | -15.2 x | -15.9 x | -16.3 x | -5.68 x | -16.6 x | -89.3 x | 12.4 x | 5.6 x |
| Yield | - | - | - | - | - | - | - | - |
| Capitalization / Revenue | 6,949 x | 34.9 x | 65 x | 4.58 x | 7.36 x | 3.18 x | 2.47 x | 1.91 x |
| EV / Revenue | 5,987 x | 27 x | 54.8 x | 1.68 x | 5.36 x | 1.64 x | 1.11 x | 1.91 x |
| EV / EBITDA | - | - | - | -2.94 x | -27.1 x | 8.93 x | 2.83 x | - |
| EV / FCF | -30 x | -17.9 x | -15.8 x | -2.81 x | -27.5 x | -73.2 x | 7.89 x | 9.66 x |
| FCF Yield | -3.34% | -5.58% | -6.32% | -35.6% | -3.63% | -1.37% | 12.7% | 10.4% |
| Price to Book | 6.89 x | 4.02 x | - | - | - | - | - | - |
| Nbr of stocks (in thousands) | 109,070 | 126,568 | 129,670 | 142,110 | 143,608 | 144,618 | - | - |
| Reference price 2 | 20.26 | 13.83 | 22.87 | 4.320 | 8.990 | 4.910 | 4.910 | 4.910 |
| Announcement Date | 3/5/20 | 2/24/21 | 2/28/22 | 2/28/23 | 2/15/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 0.318 | 50.12 | 45.6 | 134 | 175.5 | 223.2 | 287.6 | 370.8 |
| EBITDA 1 | - | - | - | -76.46 | -34.73 | 41 | 113 | - |
| EBIT 1 | -82.58 | -104.3 | -180.7 | -111.5 | -91.69 | -13.45 | 56.7 | 123.9 |
| Operating Margin | -25,967.92% | -208.09% | -396.35% | -83.17% | -52.24% | -6.03% | 19.71% | 33.41% |
| Earnings before Tax (EBT) 1 | -123.7 | -102.8 | -180.2 | -106.4 | -77.47 | -2.996 | 66.6 | 133.7 |
| Net income 1 | -123.8 | -102.7 | -181 | -108.2 | -78.02 | -6.38 | 58.79 | 128.5 |
| Net margin | -38,945.28% | -204.88% | -396.86% | -80.71% | -44.45% | -2.86% | 20.44% | 34.65% |
| EPS 2 | -1.330 | -0.8700 | -1.400 | -0.7600 | -0.5400 | -0.0550 | 0.3950 | 0.8775 |
| Free Cash Flow 1 | -63.54 | -75.44 | -158 | -79.82 | -34.18 | -5 | 40.5 | 73.5 |
| FCF margin | -19,982.08% | -150.53% | -346.47% | -59.55% | -19.47% | -2.24% | 14.08% | 19.82% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | 35.84% | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | 68.89% | 57.19% |
| Dividend per Share | - | - | - | - | - | - | - | - |
| Announcement Date | 3/5/20 | 2/24/21 | 2/28/22 | 2/28/23 | 2/15/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q3 | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 14.67 | 23.4 | 21.62 | 28.19 | 55.78 | 28.44 | 34.41 | 41.49 | 54.52 | 45.1 | 47.07 | 53.47 | 54.97 | 67.54 |
| EBITDA 1 | - | - | - | -24.94 | -0.37 | -20.98 | -19.49 | -3.282 | 1 | -12.96 | -6 | 12.9 | 12 | 22.1 |
| EBIT 1 | -50.35 | -32.7 | -37.88 | -35.99 | -9.499 | -28.1 | -29.58 | -16.17 | -16.26 | -29.67 | -18.24 | -4.66 | -0.442 | 10.17 |
| Operating Margin | -343.31% | -139.76% | -175.18% | -127.66% | -17.03% | -98.82% | -85.98% | -38.97% | -29.83% | -65.8% | -38.75% | -8.72% | -0.8% | 15.05% |
| Earnings before Tax (EBT) 1 | -50.25 | -32.6 | -37.62 | -35.51 | -8.035 | -25.19 | -25.77 | -12.13 | -13.15 | -26.42 | -16.5 | -1.662 | 2.05 | 13.14 |
| Net income 1 | -50.26 | -33.32 | -37.63 | -35.52 | -8.989 | -26.05 | -26.21 | -11.49 | -13.45 | -26.88 | -18.66 | -2.016 | 1.54 | 12.74 |
| Net margin | -342.64% | -142.4% | -174.01% | -125.98% | -16.12% | -91.6% | -76.16% | -27.7% | -24.67% | -59.6% | -39.64% | -3.77% | 2.8% | 18.86% |
| EPS 2 | -0.3900 | -0.2500 | -0.2700 | -0.2500 | -0.0600 | -0.1800 | -0.1800 | -0.0800 | -0.0900 | -0.1900 | -0.1367 | -0.0167 | 0.0117 | 0.0850 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 11/3/21 | 2/28/22 | 5/10/22 | 8/4/22 | 11/3/22 | 2/28/23 | 5/4/23 | 8/3/23 | 11/2/23 | 2/15/24 | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - | - | - |
| Net Cash position 1 | 306 | 398 | 466 | 389 | 350 | 344 | 391 | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
| Free Cash Flow 1 | -63.5 | -75.4 | -158 | -79.8 | -34.2 | -5 | 40.5 | 73.5 |
| ROE (net income / shareholders' equity) | -45.3% | -29.1% | - | - | -19.9% | -25.8% | - | - |
| ROA (Net income/ Total Assets) | - | - | - | - | - | - | - | - |
| Assets 1 | - | - | - | - | - | - | - | - |
| Book Value Per Share | 2.940 | 3.440 | - | - | - | - | - | - |
| Cash Flow per Share 2 | -0.6800 | -0.5900 | -1.220 | -0.5600 | -0.2300 | 0.0900 | 0.6700 | - |
| Capex 1 | 0.09 | 5.58 | 1.2 | 0.29 | 0.72 | 10 | 10 | 10 |
| Capex / Sales | 27.36% | 11.14% | 2.63% | 0.22% | 0.41% | 4.48% | 3.48% | 2.7% |
| Announcement Date | 3/5/20 | 2/24/21 | 2/28/22 | 2/28/23 | 2/15/24 | - | - | - |
1USD in Million2USD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
C-
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
6
Last Close Price
4.91
USD
Average target price
10.57
USD
Spread / Average Target
+115.30%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -45.38% | 710M | |
| -2.31% | 103B | |
| +0.56% | 95.28B | |
| +1.69% | 22.15B | |
| -17.37% | 21.02B | |
| -9.30% | 18.15B | |
| -41.01% | 16.74B | |
| -14.85% | 16.05B | |
| +3.21% | 13.68B | |
| +33.54% | 12.17B |
- Stock Market
- Equities
- AUPH Stock
- Financials Aurinia Pharmaceuticals Inc.
